IDEAYA Biosciences logo
IDEAYA Biosciences IDYA
$ 25.52 -2.6%
report update icon

Quarterly report 2026-Q3
added 11-03-2026

IDEAYA Biosciences Revenue | IDYA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue IDEAYA Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
219 M 7 M 23.4 M 50.9 M 27.9 M 19.5 M - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
219 M 7 M 57.9 M

Quarterly Revenue IDEAYA Biosciences

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
10.2 M 8.86 M 6.56 M 10.9 M 208 M - - 7 M - - - - 8.04 M 3.54 M 7.88 M 4.02 M 29.7 M 5.85 M 11.4 M 2.96 M 8.98 M 8.76 M 7.25 M 10.6 M 8.97 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
208 M 2.96 M 19.4 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
3.89 M $ 2.73 -9.61 % $ 22.2 M usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
67.7 M $ 10.02 5.24 % $ 1.09 B usaUSA
Adagene Adagene
ADAG
7.67 M $ 1.8 -10.56 % $ 106 M chinaChina
Denali Therapeutics Denali Therapeutics
DNLI
331 M $ 18.43 1.29 % $ 3.18 B usaUSA
Pfizer Pfizer
PFE
62.6 B $ 27.4 -0.62 % $ 156 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
214 M $ 10.56 -6.26 % $ 4.38 B irlandaIrlanda
ImmuCell Corporation ImmuCell Corporation
ICCC
27.6 M $ 11.08 -0.81 % $ 100 M usaUSA
Editas Medicine Editas Medicine
EDIT
40.5 M $ 1.63 -4.68 % $ 145 M usaUSA
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
678 M $ 93.83 0.32 % $ 6.96 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
54 M $ 27.54 -4.24 % $ 1.6 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
2.38 B $ 68.45 1.08 % $ 29.4 B usaUSA
Equillium Equillium
EQ
41.1 M $ 1.06 -5.36 % $ 60.7 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
70 M $ 1.32 -5.04 % $ 75.1 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
5.82 M $ 2.42 -1.17 % $ 128 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
1.07 B $ 17.1 -2.79 % $ 2.88 B usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
1.76 K $ 1.6 -8.86 % $ 13.8 M usaUSA
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
263 K - -7.31 % $ 49 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
190 M $ 112.31 -3.84 % $ 7.3 B usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
13.2 M - - $ 1.77 B usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
81.4 M $ 1.29 -2.28 % $ 164 M schweizSchweiz
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
868 M $ 32.58 -1.21 % $ 1.87 B usaUSA
Ardelyx Ardelyx
ARDX
407 M $ 2.99 -2.25 % $ 721 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
236 M $ 0.39 -8.41 % $ 100 M usaUSA
Alector Alector
ALEC
21 M $ 2.34 1.52 % $ 241 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
1.18 M $ 1.06 3.43 % $ 56.9 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
3.02 B $ 21.12 -1.26 % $ 6.62 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
14.1 M $ 4.03 -1.11 % $ 772 M canadaCanada
Agenus Agenus
AGEN
114 M $ 5.97 -2.85 % $ 178 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
75.1 M $ 9.63 -8.02 % $ 2.88 B canadaCanada
Aptevo Therapeutics Aptevo Therapeutics
APVO
3.11 M $ 0.4 -2.61 % $ 126 K usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
2.19 M $ 1.22 -2.4 % $ 12.1 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
7.83 M $ 3.44 -1.86 % $ 422 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
277 M $ 27.46 -2.1 % $ 4.17 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
30.3 M - -8.24 % $ 105 M germanyGermany
SIGA Technologies SIGA Technologies
SIGA
94.6 M $ 2.4 -9.06 % $ 172 M usaUSA
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
500 K - -6.97 % $ 657 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
22.3 M $ 7.56 0.4 % $ 351 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
720 M $ 28.3 0.68 % $ 1.32 B usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
524 M - 1.68 % $ 4.65 B chinaChina
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
19.4 M $ 55.64 2.88 % $ 155 M israelIsrael
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
172 M $ 8.71 -4.16 % $ 755 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
44.5 M $ 3.47 -6.48 % $ 371 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
1.58 M $ 0.59 -4.42 % $ 36.2 M usaUSA
Jaguar Health Jaguar Health
JAGX
11.5 M $ 0.24 -27.06 % $ 560 K usaUSA
Arvinas Arvinas
ARVN
263 M $ 6.41 -4.9 % $ 454 M usaUSA
Cerus Corporation Cerus Corporation
CERS
234 M $ 1.86 -2.37 % $ 355 M usaUSA